Tarsus Pharmaceuticals, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q
ASSETS
Current assets:
Cash and cash equivalents
Marketable securities	71.5	135.2	57.1		0.3	0.5
Other receivables	0.2	0.4	4.0	0.6	0.3	0.1	0.1
Prepaid expenses	5.0	4.5	3.5
Total current assets	183.5	208.6	234.1	250.3	178.8	176.0	187.1
Property and equipment, net	1.5	1.2	1.0	1.0	0.9	0.8	0.5
Operating lease right-of-use assets	2.1	0.5	0.7	0.8	0.9	1.1
Long-term investments	0.3	0.3	0.2	0.2
Other assets	1.5	0.5	0.6	0.6	0.9	1.1	1.6
Total assets	188.9	211.2	236.5	252.8	181.5	178.9	190.4

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities	9.5	9.0	10.2	8.9	10.8	8.7	8.1
Accrued payroll and benefits	5.3	4.2	4.1	2.8	1.8	2.8	2.2
Total current liabilities	14.8	13.3	14.3	11.7	12.6	11.5	10.4
Term loan, net	24.6	24.5	19.4	19.3	19.2
Other long-term liabilities	1.8	0.0	0.2	0.3	0.5	0.7	0.9
Total liabilities	41.2	37.8	33.8	31.3	32.3	12.2	11.3

Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid-in capital	311.4	305.7	297.8	294.2	216.1	213.4	211.0
Accumulated other comprehensive loss	0.0	-0.1	0.0
Accumulated deficit	-163.6	-132.2	-95.2	-72.7	-66.9	-46.7	-31.8
Total stockholders’ equity	147.7	173.4	202.6	221.5	149.2	166.7	179.1
Total liabilities and stockholders’ equity	188.9	211.2	236.5	252.8	181.5	178.9	190.4